Clinical trial
Post Marketing Surveillance of Radiotherapy With Concomitant and Adjuvant Chemotherapy With Temozolomide for Patients With Newly Diagnosed and Operated Glioblastoma Multiforme
NCT00704808 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post Marketing Surveillance of Radiotherapy With Concomitant and Adjuvant Chemotherapy With Temozolomide for Patients With Newly Diagnosed and Operated Glioblastoma Multiforme
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2006
- Completion date
- December 31, 2008
- Enrollment
- 180 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.